June 3, 2025
Sabah
Madshukv Innovation, a Sabah-based medical technology startup endorsed under Sandbox 2 NTIS, is currently progressing through its product testing and validation phase. A site visit was conducted by YBhg. Datuk Ts. Dr. Nor Azman Hassan, Deputy Secretary General (Technology Development), MOSTI, to receive firsthand updates on the company’s progress and to provide strategic facilitation for their next phase of development. Also present were YBhg. Datuk Mohd Hanafiah, Secretary General of the Ministry of Science, Technology and Innovation Sabah (KSTI Sabah); YBrs. Dr. William, Director of Hospital Queen Elizabeth I; representatives from SCENIC; and the team from Madshukv Innovation.
During the session, Madshukv highlighted two key challenges that had previously stalled their testing process: (i) the submission of their Clinical Trial Plan to MTDC, and (ii) obtaining Ethical Committee approval to conduct testing at Hospital Queen Elizabeth I, Hospital Queen Elizabeth II, and Hospital Keningau. To date, both issues have been resolved. The Clinical Trial Plan has been submitted to MTDC, and Ethical Committee approval has been obtained and is in the process of being forwarded to the relevant parties. A virtual demonstration of their medical device was presented during the visit to showcase the product’s intended application.
Madshukv also shared additional updates, including that they have initiated engagement with the Medical Device Authority (MDA) to begin the product classification and approval process. Furthermore, they will be participating in an international startup delegation to Osaka, Japan, from 24 to 29 August 2025, alongside SCENIC and several other Sabah-based startups.
